<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854775</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-292-0106</org_study_id>
    <secondary_id>2013-002780-26</secondary_id>
    <nct_id>NCT01854775</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children</brief_title>
  <official_title>A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There will be 3 cohorts in this study.

      The primary objectives of Cohort 1 are to evaluate the steady state pharmacokinetics (PK) for
      elvitegravir (EVG) and tenofovir alafenamide (TAF) and confirm the dose of the
      elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen
      (STR) (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through Week 24
      (Part B) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents.

      The primary objectives of Cohort 2 are to evaluate the PK of EVG and TAF in virologically
      suppressed HIV-1 infected children 6 to &lt; 12 years of age weighing ≥ 25 kg administered
      E/C/F/TAF STR (Part A) and to evaluate the safety and tolerability of E/C/F/TAF STR through
      Week 24 in virologically suppressed HIV-1 infected children 6 to &lt; 12 years of age weighing ≥
      25 kg (Part B).

      The primary objectives of cohort 3 are to evaluate the PK of EVG and TAF and confirm the dose
      of the STR, and to evaluate the safety and tolerability of E/C/F/TAF low dose (LD) STR in
      virologically suppressed HIV-1 infected children ≥ 2 years of age and weighing ≥ 14 to &lt; 25
      kg.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 6, 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCtau for EVG (Part A of Cohort 1,2; Cohort 3)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>AUCtau is defined as concentration of drug over a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUClast for TAF (Part A of Cohort 1 and 2)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of All Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL as Defined by the FDA Snapshot Analysis (Part B)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 50 Copies/mL as Defined by the FDA Snapshot Analysis (Part B)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 400 Copies/mL as Defined by the FDA Snapshot Analysis (Part B)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Plasma HIV-1 RNA &lt; 400 Copies/mL as Defined by the FDA Snapshot Analysis (Part B)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma log10 HIV-1 RNA (copies/mL) at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma log10 HIV-1 RNA (copies/mL) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count (cells/μL) at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CD4+ Cell Count (cells/μL) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in CD4+ Cell Count (cells/μL) at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change from Baseline in CD4+ Cell Count (cells/μL) at Week 48</measure>
    <time_frame>Baseline; Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau for EVG, FTC, TFV, and COBI (Part A)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>Ctau is defined as the observed drug concentration at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax for EVG, TAF, FTC, TFV, and COBI (Part A)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>Cmax is defined as the maximum concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Apparent CL for EVG and TAF (Part A)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>Apparent clearance (CL) is defined as the systemic clearance of the drug following oral administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Apparent Vz for EVG and TAF (Part A)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
    <description>Apparent Vz is defined as the apparent volume of distribution of the drug after oral administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau for FTC, TFV, and COBI (Part A)</measure>
    <time_frame>Predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Acquired Immune Deficiency Syndrome (AIDS)</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (12 to &lt; 18 years of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants within the ages of 12 and &lt;18 years old will receive E/C/F/TAF STR once daily with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (6 to &lt; 12 years of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants within the ages of 6 and &lt;12 years old and weighing ≥ 25 kg will receive E/C/F/TAF STR once daily with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (≥ 2 years of age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥ 2 years of age and weighing ≥ 14 to &lt; 25 kg will receive E/C/F/TAF STR once daily with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>E/C/F/TAF tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)</description>
    <arm_group_label>Cohort 1 (12 to &lt; 18 years of age)</arm_group_label>
    <arm_group_label>Cohort 2 (6 to &lt; 12 years of age)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF (Low Dose)</intervention_name>
    <description>90/90/120/6 mg STR administered orally</description>
    <arm_group_label>Cohort 3 (≥ 2 years of age)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Cohort 1

               -  12 years to &lt; 18 years of age at baseline

               -  Weight greater than or equal to 35 kg (77 lbs)

               -  Plasma HIV-1 RNA levels of ≥ 1,000 copies/mL at screening (Roche COBAS TaqMan
                  v2.0)

               -  Screening genotype report shows sensitivity to EVG, FTC and tenofovir (TFV)

               -  No prior use of any approved or experimental anti-HIV-1 drug for any length of
                  time

          -  Cohort 2

               -  6 years to &lt; 12 years of age at baseline

               -  Weight greater than or equal to 25 kg (55 lbs)

               -  Plasma HIV-1 RNA of &lt; 50 copies/mL (or undetectable HIV-1 RNA level according to
                  the local assay being used if the limit of detection is &gt; 50 copies/mL) for ≥ 180
                  consecutive days (6 months) prior to screening on a stable antiretroviral
                  regimen, without documented history of resistance to any component of E/C/F/TAF
                  STR.

          -  Cohort 3

               -  Age at baseline: ≥ 2 years old

               -  Weight at screening: ≥ 14 kg (31 lbs) to &lt; 25 kg (55 lbs)

               -  Plasma HIV-1 RNA: &lt; 50 copies/mL (or undetectable HIV-1 RNA level according to
                  the local assay being used if the limit of detection is &gt; 50 copies/mL) for ≥ 180
                  consecutive days (6 months) prior to screening on a stable antiretroviral
                  regimen, without prior history of resistance to any component of E/C/F/TAF STR

        Key Exclusion Criteria:

          -  Hepatitis B or hepatitis C virus infection

          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months
             of the screening visit.

          -  Individuals experiencing decompensated cirrhosis

          -  Pregnant or lactating females

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller's Children Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-0371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KIDCRU Ward J8</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <zip>7705</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit Baragwanath Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empilweni Services and Research Unit (ESRU)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The HIV Netherlands Australia Thailand Research collaboration (HIV-NAT)</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Savang Vadhana Memorial Hospital</name>
      <address>
        <city>Chon Buri</city>
        <zip>20110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Faculty of Medicine, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre</name>
      <address>
        <city>Kampala</city>
        <zip>PO Box 10005</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe - Clinical Research Centre</name>
      <address>
        <city>Belgravia</city>
        <zip>263</zip>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>United States</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment-naive</keyword>
  <keyword>Virologically suppressed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

